Novo Nordisk Is Losing Canadian Patent Protection on a Blockbuster Drug After Not Paying a Small Fee

Novo Nordisk is losing Canadian patent protection on a blockbuster drug after not paying a small fee

“I’m sure someone’s lost their job,” said the CEO of Sandoz, which has now filed to launch a generic GLP-1 drug in Canada next year.

Ozempic Patent Expires In Canada After Novo Nordisk Fails To Pay $450 Fee: 'It's The Second-Largest Semaglutide Market In The World,' Says Sandoz CEO Richard Saynor - Sandoz Group (OTC:SDZNY), Novo Nordisk (NYSE:NVO)

Danish pharma giant Novo Nordisk A/S (NYSE:NVO) faces potential financial losses related to its blockbuster weight-loss and diabetes drug, Ozempic, due to a regulatory issue. What Happened: About a week ago, Sandoz Group AG (OTC:SDZNY) CEO Richard Saynor, in an interview with EndPoint News, highlighted an administrative misstep by Novo in Canada that could have major ramifications for the Denmark-based company. According to Saynor, “Novo never f…

Centralization of Ozempic, Wegovy NAION Lawsuits Sought in New Jersey State Court

At least 21 Ozempic and Wegovy lawsuits involving vision loss from NAION have been brought in the state court system, according to a request to establish a multi-county litigation (MCL). Already facing thousands of Ozempic lawsuits and Wegovy lawsuits over gastrointestinal problems that have been brought in the federal court system, Novo Nordisk now also face…

Novo Nordisk Loses Canadian Patent Protection For Blockbuster Diabetes Drug Over Unpaid $450 Fee

Pharmaceutical giant Novo Nordisk forfeited patent protection for semaglutide -- the active ingredient in blockbuster diabetes and weight loss drugs Ozempic and Wegovy -- in Canada after failing to pay a $450 maintenance fee in 2019. The company had paid maintenance fees through 2018 but requested a...

$450 Error Nukes Novo Nordisk’s Ozempic Patent, Opening Canada To Generics

Novo Nordisk (NYSE: NVO) has permanently forfeited Canadian patent protection for semaglutide—the blockbuster active ingredient in Ozempic and Wegovy—after failing to pay a routine $450 maintenance invoice in 2019. Under Canada’s Patent Act, once a missed-fee grace period lapses, rights “cannot be revived,” formally clearing the way for rival filings. Canadian maintenance charges start at […]